48.24 -0.22 (-0.45%)
After hours: 7:55PM EDT
|Bid||47.00 x 100|
|Ask||48.46 x 3000|
|Day's range||47.35 - 52.43|
|52-week range||19.91 - 63.60|
|PE ratio (TTM)||N/A|
|Earnings date||25 Apr 2018 - 30 Apr 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||56.60|
Exact Sciences plunged to a six-month low Friday after first-quarter guidance was dinged by the severe flu season.
The Madison, Wisconsin-based company said it had a loss of 18 cents per share. The results surpassed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research ...
Exact Sciences (EXAS) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.
NEW YORK, Jan. 26, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Coca-Cola Bottling Co. Consolidated (NASDAQ:COKE), McGrath RentCorp (NASDAQ:MGRC), Exact Sciences Corporation (NASDAQ:EXAS), Healthcare Trust of America, Inc. (NYSE:HTA), Gramercy Property Trust (NYSE:GPT), and Apollo Commercial Real Estate Finance (NYSE:ARI), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
Shares of Exact Sciences (EXAS) are down more than 10% on Wednesday, hurt by news of a potential competitor to its test for colorectal cancer. The American Society for Clinical Oncology (ASCO) announced that a liquid biopsy shows promise at detecting early stage colorectal cancer, and more detail is expected at the association's Gastrointestinal Cancers Symposium this Saturday. In addition, the data is from a single center study in Taiwan, Myers notes, which calls for follow up research, rather than a big selloff in Exact Sciences. Exact Sciences is down 10.2% to $47.57 this afternoon.
Jim Cramer lifted the hood on Tesla’s move higher and why he thinks the stock rose despite fewer-than-expected Model 3 deliveries in Q4.
Investors attending the conference want to know if companies are planning more M&A in the wake of tax reform. Pricing practices also could be in focus.
Atlas Genetics, a rapid, near-patient and point-of-care (POC) testing company, today announced that it has appointed Stanley Lapidus to the role of independent board member on its Board of Directors. Lapidus has more than 30 years’ experience in the medical diagnostics industry as a founder, CEO and board member at companies that have dramatically impacted the diagnostics landscape, including his founding of EXACT Sciences Corp. (NASDAQ:EXAS) and, prior to that, Cytyc Corp., which was sold to Hologic Corporation in 2007. “We are honored to have Stan, a true luminary in biotechnology, join Atlas Genetics as its newest board member,” said Jeff Luber, President and CEO of Atlas.
Investors in the cancer detection company have enjoyed a phenomenal run recently, but where is this business heading in the next half-decade?